Article
Acute Lower Extremity Arterial Thrombosis Associated with Osimertinib-Induced Erythrocytosis.
The American journal of case reports - 7 Sept 2021
Kodaira Shota, Ehara Jun, Takamizawa Shigemasa, Ogita Shin, Norisue Yasuhiro, Nakama Tatsuya, Hiraoka Eiji
Abstract excerpt
BACKGROUND Osimertinib is an oral third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) approved as first-line therapy for advanced non-small cell lung cancer (NSCLC) with positive EGFR mutation. Rashes, nail toxicity, and diarrhea are common adverse events. Hematological adverse effects, including anemia, thrombocytopenia, and lymphocytopenia, have been reported. However,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.